1. Introduction

The World Health Organization (WHO) estimated that circa 2% of all human cancers occur in the central nervous system (CNS) [1]. The glioma WHO classification system includes (i) diffuse or anaplastic astrocytoma (isoctirate dehydrogenase (IDH)-wildtype/-mutant/not otherwise specified (NOS)); (ii) oligodendroglioma or anaplastic oligodendroglioma (IDH-mutant and 1p/19q-co-deletion/NOS); (iii) oligoastrocytoma or anaplastic oligoastrocytoma (NOS) and (iv) glioblastoma multiforme (GBM, IDH-wildtype/-mutant/NOS). GBM is the most common and aggressive clinical manifestation of glioma, with a 5-year survival rate of <3% compared to other primary gliomas, which have a 5-year survival rate of at least 50% [1, 2]. Patients diagnosed with primary GBM (IDH-wildtype) represent approximately 90% of cases, while those with secondary GBM (IDH-mutant) represent the...
remaining 10% [2]. The clinical outcome in patients with GBM remains poor despite advanced surgery, first-line temozolomide therapy and radiotherapy [3, 4], sometimes administered with adjunctive anti-vascular endothelial growth factor (VEGF) antibody (bevacizumab) immunotherapy [5].

Sporadic CNS inflammation has been attributed to GBM oncogenesis, with the involvement of pro-inflammatory and pleiotropic cytokines, e.g. interferon gamma (IFN-γ), tumour necrosis factor alpha (TNF-α), interleukin (IL) 6, IL-8, and IL-17A [6–8]. Non-specific inflammation may facilitate mutations in genes encoding proteins involved in the receptor tyrosine kinase pathway, including epidermal growth factor receptor (EGFR), as well as enzymes required for DNA repair and genetic stability [7]. The most frequent EGFR mutation associated with GBM is variant III of the receptor (EGFRvIII) [9, 10].

A key factor that contributes to the reduced survival of patients with GBM is the local immunosuppressive tumour microenvironment, including regulatory T-cell (Treg) induction and programmed cell death 1 (PD-1) expression [11–13]. Productive immune responses directed against tumour-associated antigens (TAA) i.e. EGFRvIII, survivin (encoded by baculoviral inhibitor of apoptosis repeat-containing 5, BIRC5 gene) or other antigenic targets are likely to be subdued. Production of immune-tolerising cytokines such as transforming growth factor beta (TGF-β), IL-10, IL-4 and IL-13, as well as the expression of the IL-13 receptor, which itself is a target for GBM immunotherapy [14] play a critical role in the balance of protective and pathological immune responses [15–17]. Temozolomide itself contributes to intratumoral immune suppression, affecting tumour-infiltrating lymphocytes (TIL) numbers as well as anti-tumour immune responses [18]. Adjunct immunotherapies e.g. tumour vaccination of patients with GBM [19] or the application of T cells expressing chimeric antigen receptors (CARs) targeting EGFvIII (clinical trials identifier: NCT02209376), IL-13 Rox2 [14], or Her2 (clinical trials identifier: NCT02442297) are currently tested in patients for safety and to improve treatment outcomes.

We studied immune responses in peripheral blood of patients using the determination of cytokines (by ELISA) and immune reactivity to specific target antigens defined by cytokine production to gain a better understanding of the global immune reactivity pattern in association with survival in patients with GBM.

2. Material and Methods

2.1. Patient Characteristics

The study was approved by the Regional Ethics Review Board (Regionella etikprövningsnämnden) at Karolinska Institutet, Stockholm (ethical permit number: 2013/576-31). 205 patients with glioma were selected to participate in the study, following written informed consent. The largest group comprised patients with GBM (WHO grade IV CNS tumour, n = 145), while patients with non-GBM glioma (n = 60) comprised individuals diagnosed with astrocytoma, oligodendroglioma/oligoastrocytoma or anaplastic oligoastrocytoma (WHO grades II–III CNS tumours) [2]. Venous blood for laboratory studies was drawn on the day of surgery and prior to initiation of cancer therapy. A description of the patient cohort is provided in Table 1.

Table 1 Summary of the clinical characteristics of patients with glioma included in this study. GBM: Glioblastoma multiforme.

| Patient characteristics | Glioma |   |   |   |
|-------------------------|--------|---|---|---|
|                         | Histology | Grade |   |   |
|                         | GBM | Non-GBM | IV | III | II |
| Sample size(N)          | 145 | 60 | 145 | 18 | 42 |
| Age median(years)       | 63 | 40 | 63 | 38 | 42 |
| Age range(years)        | 16–80 | 20–75 | 16–80 | 22–62 | 20–75 |
| Sex(male/female)        | 99/46 | 38/22 | 99/46 | 10/8 | 28/14 |

2.2. Whole Blood Assay (WBA)

Venous blood from the patients with glioma was first diluted at a ratio of 1:1.5 with RPMI 1640 Glutamax medium (ThermoFisher Scientific, Carlsbad, CA) and supplemented with antibiotics (penicillin, 100 IU/ml and streptomycin, 100 μg/ml) (ThermoFisher Scientific, Carlsbad, CA). The diluted blood was then conditioned in following manner: i) without cytokines (RPMI only); ii) human IL-7 (10 ng/ml) and IL-2 (500 IU/ml) or iii) human IL-2 (1000 IU/ml), IL-15 (10 ng/ml) and IL-21 (10 ng/ml) (Prospect, Ness-Ziona, Israel) and added to 96-well microtiter plates containing a panel of tumour-associated antigens (TAA) and viral antigens (Supplementary Table S1). The survivinβ7–111 peptide (TLEGFLKDLRERAKN) was tested separately since it induced superior immune reactivity in circulating lymphocytes and TIL in an initial screening test. The plates were incubated at 37 °C with 5% CO2 for seven days. Incubation with medium alone was used as negative control while 5 μg/ml phytohaemagglutinin (PHA, Sigma-Aldrich, St. Louis, MO), 30 ng/ml OKT3 (anti-human CD3 monoclonal antibody, Biologic, CA) and 10 ng/ml SEA+SEB (Staphylococcal Enterotoxin A and B, Sigma-Aldrich, St. Louis, MO) were used separately as positive controls.

2.3. Blood Serum Preparation and Cytokine ELISA

For plasma preparation, a fraction of whole blood was layered onto Ficol-Paque Plus solution (GE Healthcare, Uppsala, Sweden) and centrifuged at 1260 × g for 10 min. The resulting layer of serum was removed and stored at −80 °C. Cytokines (IFN-γ, TNF-α, IL-17A, IL-4, IL-5 and IL-6) as well as WBA supernatants (IFN-γ production by circulating lymphocytes) were quantified with commercially available enzyme-linked immunosorbent assay (ELISA) kits (MAbTECH, Stockholm, Sweden) according to the manufacturer’s instructions.

2.4. Immunohistochemistry

Immunostaining for survivin was performed on 4 μm sections of formalin-fixed paraffin-embedded tissue using the Leica Bond-Max automated immunostaining system (Leica Biosystems AB, Kista, Sweden). For antigen retrieval, samples were incubated for 20 min at 100 °C with Bond Epitope Retrieval Solution 1 (Leica Biosystems AB, Kista, Sweden). Slides were stained for 30 min at room temperature with the survivin polyclonal antibody RB-9245 (Thermo scientific, Carlsbad, CA), diluted at 1:200. The percentage of positive cells was evaluated using a semi-automated immunostaining system (Leica Biosystems AB, Kista, Sweden).

Slides were stained for 30 min at room temperature with the survivin polyclonal antibody RB-9245 (Thermo scientific, Carlsbad, CA) and supplemented with antibodies (penicillin, 100 IU/ml and streptomycin, 100 μg/ml) (ThermoFisher Scientific, Carlsbad, CA). The diluted blood was then conditioned in following manner: i) without cytokines (RPMI only); ii) human IL-7 (10 ng/ml) and IL-2 (500 IU/ml) or iii) human IL-2 (1000 IU/ml), IL-15 (10 ng/ml) and IL-21 (10 ng/ml) (Prospect, Ness-Ziona, Israel) and added to 96-well microtiter plates containing a panel of tumour-associated antigens (TAA) and viral antigens (Supplementary Table S1). The survivinβ7–111 peptide (TLEGFLKDLRERAKN) was tested separately since it induced superior immune reactivity in circulating lymphocytes and TIL in an initial screening test. The plates were incubated at 37 °C with 5% CO2 for seven days. Incubation with medium alone was used as negative control while 5 μg/ml phytohaemagglutinin (PHA, Sigma-Aldrich, St. Louis, MO), 30 ng/ml OKT3 (anti-human CD3 monoclonal antibody, Biologic, CA) and 10 ng/ml SEA+SEB (Staphylococcal Enterotoxin A and B, Sigma-Aldrich, St. Louis, MO) were used separately as positive controls.

2.5. Real-Time Polymerase Chain Reaction (RT-PCR)

For plasma preparation, a fraction of whole blood was layered onto Ficol-Paque Plus solution (GE Healthcare, Uppsala, Sweden) and centrifuged at 1260 × g for 10 min. The resulting layer of serum was removed and stored at −80 °C. Cytokines (IFN-γ, TNF-α, IL-17A, IL-4, IL-5 and IL-6) as well as WBA supernatants (IFN-γ production by circulating lymphocytes) were quantified with commercially available enzyme-linked immunosorbent assay (ELISA) kits (MAbTECH, Stockholm, Sweden) according to the manufacturer’s instructions.
2.6. Statistical Methods, Survival Curves, Patient Stratification

The Kaplan-Meier (K-M) survival analysis was used in order to estimate the number of patients who survived over the follow-up period of 1200 days. Univariate analysis was performed by comparing single parameters (clinical and immunological parameters as well as antigen-specific immune responses) with the overall survival of patients with GBM. Cox Proportional hazards model (forward and backward stepwise analysis) for multivariate analysis was applied to account for individual parameters/factors that could predict improved survival of patients when analysed in combination with all the parameters considered in the study. For the relationship between PBMC IFN-γ production and patient survival, cut-offs for K-M analysis were based on ‘detectable’ or ‘non-detectable’ levels (essentially detection limit provided by the manufacturer) or the median concentration values of cytokines in samples which could generate the greatest hazard ratios between two groups.

3. Results

3.1. Clinical Characteristics and Survival Pattern of Patients With Malignant Glioma

Patients with glioma (n = 205) enrolled in this study were categorised into two distinct groups: (i) patients with GBM (n = 145) and (ii) patients with non-GBM malignant glioma (n = 60; astrocytoma, oligodendroglioma or oligoastrocytoma with different subtypes). Demographic information and clinical characteristics of the patient cohort is provided in Table 1. In agreement with previous reports, patients with GBM displayed a significantly poorer survival profile compared to patients with non-GBM gliomas (18% vs 2%, p < .0001) (Fig. 1).

3.2. Detectability of Serum Cytokine Levels in Patients With Malignant Glioma

Cytokines were separated into two functional groups: (i) Th2/anti-inflammatory, comprising IL-4, IL-5 and IL-6 and (ii) Th1/inflammatory, consisting of IFN-γ, TNF-α and IL-17A. IL-6 was included in the first group due to its pleiotropic properties [21]. Between 45% and 50% of patients with GBM (WHO grade IV CNS tumour) exhibited detectable levels of IL-4, IL-5 and IL-6 in serum, while 55–60% of patients with non-GBM malignant glioma had detectable levels of each cytokine tested (Fig. 2A). Compared to patients with non-GBM malignant gliomas, a smaller fraction of patients with GBM had detectable levels of serum IFN-γ (41% vs 52%), TNF-α (12% vs 19%) and IL-17A (70% vs 78%) (Fig. 2B). We also observed that the median values of actual cytokine concentrations in the serum samples did not differ between the two patient groups (Supplementary Fig. S1).

3.3. Combinatorial Effect of Serum Cytokines on Patient Survival Patterns

Univariate analysis was then used for visualising if serum cytokine combinations affected patient survival. We found that the combination of circulating IL-4/IL-5/IL-6 – either all present or all absent (‘all’ or ‘none’) – correlated strongly with a better survival profile (p = .0022) among the patients with GBM compared to only a ‘partial’ combination i.e. one or two cytokines instead of all three (Fig. 2C). The scenario was similar for serum IFN-γ/TNF-α/IL-17A; patients with all three cytokines or none showed a tendency for an improved survival pattern (p = .0083) (Fig. 2D).

3.4. Antigen-Specific IFN-γ Production and Association With Survival Pattern of Patients With GBM

IFN-γ responses of peripheral blood mononuclear cells (PBMCs) from patients with GBM were measured by ELISA after stimulation with the antigens listed in Supplementary Table S1, with or without cytokine conditioning with IL-2/IL-15/IL-21 or IL-2/IL-7 (Methods section). CMV pp65-specific IFN-γ production by PBMCs correlated closely with a better survival profile of the patients in the presence of IL-2/IL-15/IL-21 conditioning (Fig. 3A). This was also found to be true for IFN-γ production in response to EBNA-1 (Fig. 3B), EBNA-3a (Fig. 3C) and the survivin97-111 peptide TGLFKLDRERAKN (Fig. 3D). Conversely, IFN-γ production in response to the NY-ESO180_94 peptide ARGPESSLLEFYLM or EGFvIII113 peptide LEEKKGNYVVDTH did not correlate with improved survival of patients with GBM (data not shown). The survivin97-111 peptide was tested separately, in addition to the survivin peptide mix due to its strong induction of IFN-γ production in TIL and PBMCs in an initial screen performed in our laboratory (data not shown).

3.5. Targeted IFN-γ Responses to Survivin97–111 Is Associated With Improved Survival of Patients With GBM

Clinical and immunological parameters, as well as the antigen-specific immune responses were submitted to univariate analysis to test their relationship to patient survival (Table 2). The more general immunological factors are distinguished from the antigen-specific immune responses: the former designate (non-antigen-specific) serum cytokines measurements, while the latter represent target-specific IFN-γ production in peripheral blood with or without cytokine conditioning. The following clinical and immunological parameters were found to be strongly associated with improved survival of patients with GBM: age (p = .0439), tumour recurrence (p = .0397), Karnofsky Performance Status (KPS) of patients (p = .0258), radiotherapy (p < .0001), chemotherapy (p < .0001), serum levels of IL-4/IL-5/IL-6 (p = .0022) as well as IFN-γ/TNF-α/IL-17A (p = .0083). Antigen-specific immune responses, defined by IFN-γ production of PBMCs to EBNA-1 (p < .0001), EBNA-3a (p = .0091), CMV pp65 (p = .0238) as well as the survivin97-111 peptide TGLFKLDRERAKN (p = .0152) also correlated with improved survival of patients with GBM, yet only in the presence of IL-2/IL-15/IL-21 (Table 2). None of the antigen-specific immune response parameters in the unconditioned and in IL-2/IL-7-conditioned groups were statistically significant (data not shown).
lesions were also confirmed by immunohistochemistry and polymerase chain reaction, respectively (Fig. 4), in agreement with previous reports [22, 23]. 15/25 patients with GBM (60%) exhibited high expression (≥20%) of survivin protein in the tumour tissue based on immunohistochemistry data (data not shown).

4. Discussion

Cytokine networks appear to be crucial in cancer initiation and disease establishment [24, 25] orchestrating immune responses that sustain health or promote disease. This report provides the first evidence that a combination of serum IL-4/IL-5/IL-6 or IFN-\(\gamma\)/TNF-\(\alpha\)/IL-17A, detectable prior to surgery and cancer therapy, can predict the survival profile of patients with GBM in the follow-up phase (see Supplementary Fig. S5 for the consort diagram). We also show that circulating T cells specific for EBV, CMV, or the survivin\(\_{97-111}\) peptide target can be conditioned with a cocktail of IL-2/IL-15/IL-21 to produce IFN-\(\gamma\) which correlates with patient survival. To the best of our knowledge, this is also the first study describing PBMC reactivity gauged by IFN-\(\gamma\) production to a single survivin peptide, as an independent predictor of improved survival among patients with GBM.

Chiorean and colleagues reported previously an association between the upregulation of serum IL-8, endothelial hyperplasia as well as coagulation necrosis, while VEGF upregulation was found to be linked with ischemic necrosis in patients with GBM [8]. The authors, however, did not find any correlation with patient survival. Previous studies have assessed individual serum cytokines in relation to the survival of patients with cancer [26, 27], although the effect of cytokine networks

3.6. Multivariate Analysis of Parameters to Visualise Independent Predictors of Survival in GBM

Next, we determined whether the above-mentioned parameters/factors could independently affect the survival of patients with GBM using multivariate analysis. All parameters and factors that gave a p value of <0.05 in the univariate analysis, including data from the three separate culture conditions (non-cytokine-conditioned blood, IL-2/IL-7-conditioned and IL-2/IL-15/IL-21-conditioned), that were fitted into the forward-backward stepwise Cox regression model (proportional hazards). Parameters that resulted in a significant p value (<0.05) pertaining to the survival pattern of patients with GBM are listed in Table 3. Radiotherapy (p < 0.0001; HR = 0.3368), chemotherapy (p = 0.028; HR = 0.7143) and the combination of detectable levels of serum IFN-\(\gamma\)/TNF-\(\alpha\)/IL-17A correlated positively with an improved survival profile (p = 0.003; HR = 1.7851), with borderline significance for serum IL-4/IL-5/IL-6 (p = 0.052; HR = 2.2645). PBMC produced IFN-\(\gamma\) in response to survivin\(\_{97-111}\) peptide only with IL-2/IL-15/IL-21 conditioning (and not in the presence of IL-2/IL-7 or ‘unconditioned’), and was identified as the sole factor reflecting an antigen-specific immune response associated with improved survival of the patients (p = 0.024; HR = 2.0756) (Supplementary Fig. S2). Approximately 24% of patients with GBM exhibited IFN-\(\gamma\) responses to the survivin\(\_{97-111}\) peptide in peripheral blood conditioned with IL-2/IL-15/IL-21 (Supplementary Fig. S2). The effect of EBNA-1-specific IFN-\(\gamma\) production (with IL-2/IL-15) on patient survival followed a similar trend to the survivin peptide, albeit with borderline statistical significance (p = 0.051; HR = 1.6397). Survivin protein expression and gene (BIRC5) transcription in GBM
remained underexplored. Cytokine networks, rather than individual cytokines, provide a ‘high-resolution’ insight into disease mechanisms involved in pathogenesis and progression i.e. the IL-15/IL-32 network in pulmonary tuberculosis (a pertinent example of chronic inflammation) [28], the IL-17/IL-6/TNF-α/TGF-β axis in colorectal cancer [24] and IFN-γ/IL-6/TNF-α/IL-1β cross-talk in atherosclerosis [29]. In line with this, the pleiotropic cytokine IL-6 can support plasma cell differentiation and maintenance in the host synergistically with IL-5, in addition to promoting inflammation on its own [21, 30]. Together with IL-4, IL-6 can trigger the reduction of circulating Treg numbers by promoting FoxP3 downregulation, which is highly favourable for successfully cell-based therapies in cancer [31]. Thus, the combinatorial effect of IL-4, IL-5 and IL-6 may help to control the tumour burden in patients by sustaining the production of TAA-specific antibodies as well as antigen-specific T-cell reactivity without Treg-associated disruption of productive immune responses [32]. IL-4 and IL-5 can nevertheless be involved in inflammatory processes; IL-5 is associated with eosinophil induction in airway hyperreactivity and asthma [33], while IL-4 upregulation is linked to IL-12p40 production by dendritic cells, TH1 cell induction and cytotoxic lymphocyte activation [25, 34]. Since a survival benefit was also observed when no serum cytokines were detected, the total absence of systemic hyper-immune activation may be as likely as the presence of a balanced cytokine network, in this case IL-4/5/6 and/or IFN-γ/TNF-α/IL-17A, to contribute to clinically relevant and durable anti-tumour immune responses that may be considered biologically relevant in clinical immune-monitoring (Fig. 5).

Furthermore, no statistical significance was seen when the individual cytokines were tested for an effect on survival benefit (Supplementary Fig. S6).

We observed that exclusively in the presence of IL-2/IL-15/IL-21 conditioning, detectable anti-survivin97-111 IFN-γ production by PBMCs correlated with 70% of survival at 600 days post-surgery (also reflected in the multivariate analysis) as opposed to under 25% among non-responding patients with GBM. Encoded by the BIRC5 gene, survivin is an anti-apoptotic protein which associates with caspase-9 to inhibit the intrinsic apoptotic pathway, while promoting mitosis in cells; its overexpression in cancer cells perpetrates uncontrolled proliferation leading to disease progression [35, 36]. Downregulation of survivin expression in glioblastoma cell lines (G55T2 and U-87 MG) via siRNA-based knockdown of the Special AT-rich Sequence-Binding Protein 1 (SATB1) regulator has been shown to induce apoptosis and cell growth arrest [37]. Furthermore, the survivin-based conjugate vaccine SurVaxM was recently tested in a phase I clinical trial involving patients with GBM (NCT02455557), while IMA950, a multi-peptide conjugate vaccine candidate also incorporating the survivin/protein 1 (SATB1) regulator has been shown to induce apoptosis and cell growth arrest [37]. Moreover, the survivin-based conjugate vaccine SurVaxM was recently tested in a phase I clinical trial involving patients with GBM (NCT02455557), while IMA950, a multi-peptide conjugate vaccine candidate also incorporating the survivin-based conjugate vaccine SurVaxM was recently tested in a phase I clinical trial involving patients with GBM (NCT02455557), while IMA950, a multi-peptide conjugate vaccine candidate also incorporating the survivin/TLGEFLKLDRERAKN conjugate vaccine was recently tested in a phase I clinical trial involving patients with GBM (NCT01920191) for HLA-A*02+ individuals [38]. The survivin97-111 TLGEFLKLDRERAKN peptide is also presented by frequent HLA-DR alleles (which trigger CD4+ T-cell responses) [39, 40]. We could also detect survivin-directed immune reactivity among CD4+ and CD8+ TIL in patients with GBM (Supplementary Fig. S4). We have previously shown that TIL from GBM and pancreatic adenocarcinoma, after cultivation with IL-2/IL-15/IL-21, display properties that are highly desirable for
Table 2
Univariate analysis of clinical and immunological parameters in relation to survival of patients with GBM.

| Factor                          | P value |
|--------------------------------|---------|
| Clinical                        |         |
| Age                             | 0.0419* |
| Median                          |         |
| Range 16–80                     |         |
| Gender                          | 0.5543  |
| M                               |         |
| F                               | 0.46    |
| Recurrence                      | 0.0397* |
| 2                               |         |
| 15                              |         |
| 35                              |         |
| 0                               |         |
| Tumour diameter (cm)            | 0.7450  |
| Median                          |         |
| Range 1–8                       |         |
| Radiology Oedema                | 0.1079  |
| No                              |         |
| Moderate                        | 0.79    |
| Severe                          | 0.57    |
| Tumour Localisation             | 0.4205  |
| Frontal                         |         |
| Parietal                        | 0.30    |
| Temporal                       | 0.59    |
| Rest                            | 0.16    |
| Mental status                   | 0.0594  |
| Normal                          |         |
| Minor confusion                 | 0.25    |
| Major/Gross confusion or Unconscious |     |
| 9                               |         |
| KPS score                       | 0.0258* |
| >80                             | 0.104   |
| ≤80                            | 0.41    |
| RPA classification before surgery | 0.0435* |
| 5 + 6                          | 0.121   |
| 3/4                            | 0.22    |
| 0                              | 0.02174 |
| Extent of resection             |         |
| Complete                        | 0.65    |
| Partial                         | 0.77    |
| ND                             | 0.03    |
| Radiotherapy                    | -0.0001*|
| Yes                            | 0.107   |
| No                             | 0.37    |
| ND                             | 0.01    |
| Chemotherapy                    | -0.0001*|
| ≥2                             | 0.72    |
| 1                              | 0.67    |
| 0                              | 0.08    |
| Infection                       | 0.1191  |
| Yes                            | 0.127   |
| No                             | 0.18    |
| Immunological                   |         |
| Serum IL-4/IL-5/IL6             | 0.0022* |
| All or none                     | 0.112   |
| Partial                         | 0.23    |
| ND                             | 0.01    |
| Serum IFN-γ/TNF-α/IL-17A        | 0.0083* |
| All or none                     | 0.55    |
| Partial                         | 0.80    |
| ND                             | 0.10    |
| Antigen-specific immune response |         |
| EBNA-1 (IL-2/15/21)             | -0.0001*|
| IFN < 460.5 pg/ml               | 0.70    |
| IFN ≥460.5 pg/ml                | 0.71    |
| ND                             | 0.04    |
| EBNA-3a (IL-2/15/21)            | 0.0091* |
| IFN < 86.1 pg/ml                | 0.70    |
| IFN ≥86.1 pg/ml                 | 0.71    |
| ND                             | 0.04    |
| CMV Pgp65 (IL-2/15/21)          | 0.0238* |
| IFN < 224.5/ml                  | 0.70    |
| IFN ≥224.5/ml                   | 0.71    |
| ND                             | 0.04    |
| Survivin97-111 (IL-2/15/21)     | 0.0152* |

Table 2 (continued)

| Factor                          | P value |
|--------------------------------|---------|
| Undetectable                   | 0.102   |
| Detectable                      | 0.32    |
| ND                             | 0.011   |

KPS: Karnofsky Performance Status; RPA: Recursive Partitioning Analysis; ND: Not defined.
* Included in multivariate analysis.

This study has several benefits for strengthening future personalised immunotherapy as well as immune-monitoring protocols. The WBA (whole-blood-assay) can be easily used to screen patients with GBM or advanced cancers of different histologies for the presence of survivin97-111-specific T cells, which may be isolated and expanded in vitro with IL-2/IL-15/IL-21 for reinfusion. Additionally, peptide-specific T-cell receptors (TCRs) recognising survivin97-111 may be cloned and transferred for transgenic expression in effector T cells, as was recently reported for the KRAS G12D mutation in patients with colorectal cancer [49]. The significance of cytokine networks i.e. IL-4/IL-5/IL-6 and IFN-γ/TNF-α/IL-17A in predicting patient survival also broadens the examination of other biological mediators that can be easily measured in blood samples using established and qualified diagnostic methods.

Table 3
Forward and backward stepwise multivariate analysis model of confirmed prognostic variables (Cox proportional hazards model) from univariate analyses to determine single factors to predict survival of patients with GBM.

| Variable                        | Stepwise (COX) HR | P value | 95% CI |
|---------------------------------|------------------|---------|--------|
| Radiotherapy                    | Radiotherapy     | 0.3368  | <0.0001| 0.20435| 0.55502 |
| Chemotherapy                    | Chemotherapy     | 0.7143  | 0.028 | 0.52857| 0.96521 |
| EBNA1                           | EBNA1            | 1.06397 | 0.051 | 0.99820| 2.69339 |
| Survivin97-111                  | Survivin97-111   | 2.0756  | 0.024 | 1.09916| 3.91960 |
| IL-4/5/6                       | IL-4/5/6         | 1.7851  | 0.052 | 0.99532| 3.19990 |
| IFN-γ/TNF-α/IL-17A             | IFN-γ/TNF-α/IL-17A| 2.2645 | 0.003 | 1.33067| 3.85354|
Fig. 4. Intratumoral survivin/BIRC5 expression in relation to survival of patients with GBM. Kaplan-Meier survival analyses showing BIRC5 gene expression (A) as well as survivin protein expression (B) in GBM tissue samples in relation to the survival pattern of patients with GBM. Molecular analysis of BIRC5 gene transcription levels in GBM tissue was measured by real-time polymerase chain reaction, while survivin protein expression in paraffin-embedded GBM tissue sections was detected using immunohistochemistry. For BIRC5 gene transcription, low expression indicates a delta cycle threshold (CT) value of ΔCT ≥ 6.4, while high expression indicates a delta CT value of ΔCT < 6.4. Twenty samples from patients with GBM were tested. ΔCT range was 3.56–10.00 and the median ΔCT value was 6.4. Thirteen samples exhibited ΔCT ≥ 6.4 and the remaining seven samples ΔCT < 6.4.

Acknowledgement

We are thankful for Dr. Lalit Rane’s assistance (PCR) and Dr. Christoph Illies for the survivin staining in GBM tissue (immunohistochemistry).

Funding Sources

This study was supported by the Söderberg Foundation to MM. The funding agency was not involved in study design, data collection, data analysis, interpretation, writing of the report.

Conflicts of Interest

The cytokine cocktail IL-2, IL-15 and IL-21 has been filed for IP with regard to TIL expansion and antigen-specific T-cells (E.D., M.M.).

Fig. 5. Schematic representation of the contribution of cytokine networks to the survival dynamics of patients of GBM. As presented in this study, the absence (far left of the diagram) or presence (far right of the diagram) of the combination of circulating IL-4/IL-5/IL-6 or IFN-γ/TNF-α/IL-17A measurable in blood reflects a favourable prognosis for improved survival of patients with GBM (grade IV brain tumour). Conversely, the presence of only one or two of the cytokines, shown in the middle section of the diagram, does not appear to favour the survival of these patients based on our data. Thus, the role of cytokine networks in GBM summarised in this figure could serve as a starting point for biological and clinical validation as a reliable biomarker in larger cohorts of patients with glioma.

Author Contributions

LZ performed the experiments, analysed and interpreted the data, prepared the figures and wrote the manuscript; MR performed the literature search, wrote the manuscript and provided scientific input; XL provided assistance with statistical analyses and scientific input; DV provided assistance with statistical analyses, Avd, QM and NH provided technical assistance with experiments; GS provided patient material and relevant clinical information; JK contributed with technical input; H-MA contributed with scientific input; EJ contributed to the study design and provided scientific input; I-HP contributed to the study design; ED contributed to the study design and provided patient material as well as relevant clinical information; MM designed and initiated the study, interpreted the data, provided scientific input and wrote the manuscript.

Disclaimer

The authors declare that the cytokine cocktail IL-2, IL-15 has been filed for IP (ED, MM).

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.ebiom.2018.06.014.

References

[1] WHO. World Cancer Report 2014. Lyon: International Agency for Research on Cancer, World Health Organisation; 2014.
[2] Louis DN, Perry A, Reifenberger G, et al. The 2016 world health organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 2016;131(6):803–20.
[3] Vaios EJ, Nahed BV, Muzikansky A, Fathi AT, Dietrich J. Bone marrow response as a potential biomarker of outcomes in glioblastoma patients. J Neurosurg 2016:1–7.
[4] Barani IJ, Larson DA. Radiation therapy of glioblastoma. Cancer Treat Res 2015;163:49–73.
[5] Larson EW, Peterson HE, Lamoraux WT, et al. Clinical outcomes following salvage Gamma Knife radiosurgery for recurrent glioblastoma. World J Clin Oncol 2014;5(2):142–8.
[6] Wainwright DA, Sengupta S, Han Y, Ulasov IV, Lesniak MS. The presence of IL-17A and T helper 17 cells in experimental mouse brain tumors and human glioma. PLoS One 2010;5(10):e15390.
[7] Sowers JL, Johnson KM, Conrad C, Patterson JT, Sowers LC. The role of inflammation in brain cancer. Adv Exp Med Biol 2014;816:75–105.
[8] Chionoan R, Berindan-Neagoe I, Braicu C, et al. Quantitative expression of serum biomarkers involved in angiogenesis and inflammation, in patients with glioblastoma multiforme: correlations with clinical data. Cancer Biomarkers 2014;14(2–3):185–94.
[9] Gan HK, Cvrljevic AN, Johns TG. The epidermal growth factor receptor variant III (EGFRVIII): where wild things are altered. FEBS journal – FEBS J 2013;280(21):5250–70.

[10] Pedersen MW, Melton M, Damstrup L, Poulsen HS. The type III epidermal growth factor receptor mutation. Biological significance and potential target for anti-cancer therapy. Ann Oncol 2001;12(6):745–60.

[11] Wajnberg K, Glioblastoma-derived mechanisms of systemic immunosuppression. America –– Neurosurg Clin N Am 2010;21(1):31–42.

[12] Antonios JP, Soto H, Everson RG, et al. PD-1 blockade enhances the vaccination-induced immune response in glioma. JCI Insight 2016;1(10).

[13] Kastler L, Dwyer D, Qin FX. Synergistic effect of IL-6 and IL-4 in driving fate revision of natural Foxp3+ regulatory T cells. J Immunol 2010;185(10):5778–86.

[14] Fumio K, Okamura T, Sumimoto S, Yamamoto K. Regulatory T cell-mediated control of autoantibody-induced inflammation. Front Immunol 2012;3:28.

[15] Mukherjee M, Sehmi R, Nair P. Anti-IL-5 therapy for asthma and beyond. World Allerg Org J 2014;7(1):32.

[16] Harshyne LA, Nasca BJ, Kenyon LC, Andrews DW, Hooper DC. Serum exosomes and immunosuppressive mechanisms of malignant gliomas. JCI Insight 2016;1(10).

[17] Winograd EK, Ciesielski MJ, Fenstermaker RA. Novel vaccines for glioblastoma: clinical update and perspective. Immunotherapy 2016;8(11):1293–308.

[18] Widegren M, Griesemann H, Stevanovic S, et al. Promiscuous survivin peptide induces robust CD4+ T-cell responses in the majority of vaccinated cancer patients. Int J Cancer 2012;131(1):140–9.

[19] Rando T, Herold-Mende C, Hill N, et al. Exploiting the glioblastoma peptidome to discover novel tumour-associated antigens for immunotherapy. Brain 2012;135(Pt 4):1042–54.

[20] Liu Z, Meng Q, Bartek Jr J, et al. Tumor-infiltrating lymphocytes (TILs) from patients with glioma. Oncoimmunology 2017;6(2):e1252894.

[21] Meng Q, Liu Z, Rangelova E, et al. Expansion of tumor-reactive T cells from patients with pancreatic cancer. J Immunother 2016;39(2):81–6.

[22] Riddell SR, Watanabe KS, Goodrich JM, Li CR, Agha ME, Greenberg PD. Restoration of natural Foxp3+ regulatory T cells by IL-24. Science 1992;257(5067):238–41.

[23] Ichihara V, Kayser S, Wolff D, et al. Adoptive transfer of epstein-barr virus (EBV) nucleic antigen 1–specific T cells as treatment for EBV reactivation and lymphoproliferative disorders after allogeneic stem-cell transplantation. J Clin Oncol 2013;31(1):39–48.

[24] La Rosa C, Diamond DJ. The immune response to human CMV. Future Virol 2012;7(3):279–93.

[25] Merlo A, Turini R, Dolcetti R, et al. The interplay between Epstein–Barr virus and the immune system: a rationale for adoptive cell therapy of EBV-related disorders. Haematologica 2010;95(10):1769–77.

[26] Nagu T, Aboud S, Rao M, et al. Strong anti-Epstein Barr virus (EBV) or cytomegalovirus (CMV) cellular immune responses predict survival and a favourable response to anti-tuberculosis therapy. Int J Infect Dis 2017;56:136–9.

[27] Dietrich J, Rao K, Pastorio S, Kesari S. Corticosteroids in brain cancer patients: benefits and pitfalls. Expert Rev Clin Pharmacol 2011;4(2):233–42.

[28] Tran E, Robbins PF, Lu VC, et al. T-cell transfer therapy targeting mutant KRAS in cancer. N Engl J Med 2016;375(23):2255–62.